Osteoporosis, a condition marked by the deterioration of bone microarchitecture and increased facture risk, arises from a disruption in bone metabolism, with osteoclasts surpassing osteoblasts in bone resorption versus formation. The Wnt signalling pathway, a key regulator of bone maintenance, remains partially understood in osteoporosis. Our research delves into the role of Wnt‐related molecules in this disease. In osteoporotic adipose‐derived stem cells (OP‐ASCs), we detected a significant decrease in Ctnnb1 and Frizzled‐6 (Fzd6), contrasted by an increase in Gsk‐3β and Wnt5a. Activation of the Wnt pathway by LiCl resulted in elevated Ctnnb1 and Fzd6, but decreased Gsk‐3β and Wnt5a levels, promoting OP‐ASCs' bone‐formation capacity. In contrast, inhibition of this pathway by DKK‐1 led to diminished Ctnnb1 and Fzd6, and increased Gsk‐3β and Wnt5a, adversely affecting osteogenesis. Furthermore, our findings show that overexpressing Wnt5a impedes, while silencing it enhances the bone‐forming capability of OP‐ASCs. In a cranial bone defect model, the implantation of Wnt5a‐silenced OP‐ASCs with biphasic calcium phosphate scaffolds significantly promoted new bone formation. These observations indicated a repression of the canonical Wnt pathway and a stimulation of the non‐canonical pathway in OP‐ASCs. Silencing Wnt5a increased the osteogenic and regenerative abilities of OP‐ASCs. Our study suggests targeting Wnt5a could be a promising strategy for enhancing bone regeneration in post‐menopausal osteoporosis.